Adderall Shortage: Causes and Prescription Access

In 2022 and 2023, the United States experienced a significant shortfall in the production of stimulant medications, including Adderall, with an estimated one billion fewer doses produced than allowed by the Drug Enforcement Administration (DEA) regulations in each year1 . This shortage has impacted millions of people diagnosed with attention-deficit hyperactivity disorder (ADHD), complicating access to essential medications and disrupting treatment plans2 . Understanding the causes of this shortage and knowing how to navigate prescription access challenges are critical for patients and healthcare providers alike.

Adderall Supply and Demand Issues

The shortage of Adderall, a widely prescribed stimulant for ADHD, is the result of a complex interplay of factors involving both supply constraints and increased demand. Drug shortages in the U.S. are a persistent public health problem, often caused by multifactorial issues such as manufacturing delays, supply chain disruptions, and regulatory limitations3 . The COVID-19 pandemic further exposed vulnerabilities in pharmaceutical production and distribution, exacerbating shortages across many drug classes, including stimulants4 .

• Increased Demand
  The demand for stimulant medications has risen sharply over the past decade. From 2012 to 2021, stimulant prescription fills increased by 45%, driven by greater awareness and diagnosis of ADHD and reduced stigma around treatment5 . Pandemic-era policies allowing telehealth prescribing without in-person visits also expanded access, contributing to a surge in prescriptions5 . This rise in legitimate medical need has been compounded by recreational misuse, which further strains supply5 .
• Regulatory Production Limits
  Adderall and similar stimulants are Schedule II controlled substances due to their high potential for abuse5 . The DEA sets strict annual production quotas to limit the total amount manufactured. Despite these quotas, many manufacturers have historically produced below their allowed limits, contributing to shortages. In 2022 and 2023, manufacturers produced approximately 30% less than their quotas, resulting in a billion-dose shortfall1 . The DEA has since increased quotas and tightened reporting requirements to encourage full utilization of production capacity6 .
• Manufacturing and Supply Chain Issues
  Some manufacturers, including Teva Pharmaceuticals, have experienced intermittent production delays and shortages of active ingredients, limiting their ability to meet demand7 8. Supply chain disruptions related to the pandemic and economic factors such as low profitability for generic manufacturers have also contributed to limited availability9 3. Several manufacturers have discontinued certain formulations, further reducing supply options8 .
• Impact on Other ADHD Medications
  The shortage of Adderall and its generic equivalents has caused a domino effect, leading to limited supplies of other stimulant medications such as Vyvanse and methylphenidate-based drugs10 . While extended-release formulations like Adderall XR and brand-name Vyvanse remain more available, their generics are increasingly affected by shortages5 10. This scarcity has forced some patients, especially children, to switch to alternative stimulants or non-stimulant therapies2 .

💡 Did You Know?
In both 2022 and 2023, the DEA estimated a one billion dose shortfall in stimulant production, meaning the U.S. produced a billion fewer doses of Adderall, Vyvanse, Ritalin, and Concerta than allowed by regulation1 .

Research analyzing national prescription data from 2017 to 2023 shows that the Adderall shortage led to decreased dispensing rates of Adderall among children, particularly male adolescents, while prescriptions for alternative stimulants like dexmethylphenidate (Focalin) increased2 . Although many children continued stimulant therapy, some were forced to switch medications, which may affect symptom control2 . Adults have also contributed to increased demand, potentially limiting access for pediatric patients2 .

“Our findings suggest that the Adderall shortage did not cause many children to stop stimulant therapy altogether, but it did force some to switch to alternative stimulants.”

— Sijia He, M.S., University of Michigan2

The shortage has caused significant psychological and functional impacts on patients. Individuals with ADHD report difficulties in accessing medications, financial strain, and frustration with complex healthcare systems11 . The stigma associated with repeatedly seeking controlled substances and the burden of calling multiple pharmacies to locate medication add to the challenges11 .

“The CDC has issued a health advisory regarding potential disrupted access to prescription stimulant medications and possible increased risks for injury and overdose.”

— Leslie Jensen, PharmD, University of Utah8

What to Do If Your Pharmacy Is Out of Stock

Facing an Adderall shortage can be stressful and disruptive to treatment. While no official guidelines provide specific steps for patients during this shortage, general strategies can help manage the situation safely and effectively.

• Contact Your Healthcare Provider Promptly
  If your pharmacy does not have your medication, reach out to your prescribing provider as soon as possible. They can assess your situation, discuss alternative medications or dosages, and help develop a plan to maintain symptom control5 . Providers may recommend therapeutic substitution or dose adjustments under clinical supervision3 .
• Call Multiple Pharmacies
  Medication availability can vary by location and pharmacy chain. Calling ahead to check stock at different pharmacies, including smaller or hospital pharmacies, may help locate your medication5 . Pharmacists may also provide information about expected restock dates or alternative options8 .
• Consider Alternative ADHD Medications
  There are several stimulant and non-stimulant medications approved for ADHD treatment. Alternatives include other amphetamine-based drugs (e.g., Vyvanse, Dexedrine) and methylphenidate-based drugs (e.g., Ritalin, Concerta), as well as non-stimulants like atomoxetine (Strattera) and guanfacine (Intuniv) 510. Switching medications should always be done under medical supervision to ensure safety and effectiveness.
• Avoid Self-Medication or Illicit Sources
  Some patients may be tempted to obtain medications from unregulated sources or alter dosages without guidance. This is dangerous and can lead to adverse effects, compromised treatment, and legal risks11 12. Always consult your healthcare provider before making any changes.
• Explore Supportive Therapies
  Behavioral therapy, lifestyle modifications, and ADHD coaching can complement medication treatment and help manage symptoms during shortages5 10. Your provider can guide you on integrating these approaches.

Patients report that navigating the shortage is complicated by limited information from pharmacies, insurance hurdles, and stigma from healthcare providers when requesting multiple refills or transfers11 . These barriers can delay access and increase stress. Transparent communication from pharmacies and providers is essential to support patients during this time11 .

“The Adderall shortage has caused a lot of challenges for patients with ADHD. If you have a concern about a potential shortage, talk to your doctor as soon as you can to get a plan in place.”

— Dr. Michael Chichak, MD, MEDvidi5

• Request prescription refills early to avoid running out5 .
• Ask your provider about partial refills if full supply is unavailable5 .
• Use manufacturer coupons or patient assistance programs to reduce costs11 .
• Keep a list of pharmacies in your area and call ahead to check availability5 .
• Maintain open communication with your healthcare team about symptom changes or side effects5 .

“FDA is in frequent communication with all manufacturers of amphetamine mixed salts, and one of those companies, Teva, is experiencing ongoing intermittent manufacturing delays.”

— FDA, U.S. Food and Drug Administration7

Drug shortages can also increase healthcare costs and resource use, especially when substitutions or dose changes are needed12 . It is important to work closely with healthcare professionals to minimize risks and optimize treatment.